Skip to content

Protagonist Therapeutics PTGX Change in Lease Liabilities

Change in Lease Liabilities at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
-$1.21M-7.5%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$56.4M+99.0%
Operating income-$3.6M+81.1%
Net income$3.8M+132%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$193.7M+38.7%
Total debt$9.8M-13.9%
Total equity$655.5M-4.9%
Total assets$697.5M-6.0%

Cash flow

See full
Operating cash flow-$48.9M-139%
CapEx$215.0K-60.6%
Free cash flow-$49.2M-139%

Valuation

See full
Market cap$7.26B+127%
Enterprise value$7.07B+130%
P/S98×+82.6×

Profitability

See full
Operating margin-192.4%-205pp
Net margin-154.9%-182pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity-17.1%-26.1pp
Debt / equity0.0×
Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Protagonist Therapeutics's change in lease liabilities?
Protagonist Therapeutics (PTGX) reported change in lease liabilities of -$547K in Q1 2026.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.